Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control

Figures & data

Table 1 Demographic characteristics of the 22 patients who completed the study

	Gender
	Males n = 17	Females n = 5
Age (years)	61.3 ± 8.6	58.7 ± 7.1
Weight (kg)	104.5 ± 23.4	90.1 ± 22.8

Note: All values for ages and weight are expressed as the median ± standard deviation.

Table 2 Effect of adjunctive Berberol therapy after 90 days of treatment in 22 patients with type 2 diabetes and suboptimal glycemic control

Parameter	t = 0	t = 90	Δ%	P value
HbA1c (%)	8.0 ± 0.82	7.15 ± 1.09	−10.6	0.003
TC (mg/dL)	191 ± 40	151 ± 37	−21	0.002
LDL-C (mg/dL)	107.6 ± 36	87 ± 34	−19.2	0.013
HDL-C (mg/dL)	46.0 ± 10.7	44.0 ± 10.9	−4.35	ns
Triglycerides (mg/dL)	170 ± 81	95 ± 45	−44.1	0.012
FG (mg/dL)	149.5 ± 21.3	122 ± 44.02	−18.4	ns
BI (μU/mL)	22.7 ± 11.8	15.5 ± 7.9	−34.4	0.04
Body mass index (kg/m^2)	34.4 ± 6.5	34.1 ± 9.9	−0.3	ns
Weight (kg)	101.3 ± 23.6	100.6 ± 24.1	−0.7	ns
Waistline (cm)	116.9 ± 14.7	116.2 ± 14.5	−0.4	ns
HOMA-R	6.9 ± 3.6	5.1 ± 3.6	−26.1	0.04

Notes: All values are expressed as the median ± standard deviation at baseline (t = 0) and after 90 days (t = 90) of daily therapy. Δ% corresponds to the difference (percent) between t = 0 and t = 90.

Abbreviations: BI, basal insulin; FG, fasting glucose; HOMA-R, homeostatic model assessment of insulin resistance (FG × BI/405); LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA_1c, glycosylated hemoglobin; ns, not statistically significant; TC, total cholesterol.